Videos

Ian Flinn, MD, PhD, describes some of the important unmet needs of DLBCL, particularly in R/R DLBCL, and shares his hopes for the future of treatment.

An oncologist shares which treatment regimen he would recommend next for this patient with DLBCL who experienced two disease relapses and reflects on how CD19- and CD79b-targeted therapies have impacted patient outcomes in the field.

Dr Ian Flinn explains the available treatment options for patients with DLBCL who experience 2 or more relapses, and the situations in which he would use each regimen.

An expert provides his perspective on the first- and second-line treatment approaches in the patient case and comments on the patient’s likely prognosis.

Ian Flinn, MD, PhD, presents the case of a 68-year-old man with diffuse large B-cell lymphoma (DLBCL) and 2 relapses after complete disease remission.

Naveen Pemmaraju, MD, shares the critical unmet needs in the myeloproliferative neoplasm treatment landscape.

A key opinion leader details the single-agent therapies currently being investigated for the treatment of myeloproliferative neoplasms.

Dr Pemmaraju explains the rationale for ruxolitinib combination therapies in myeloproliferative neoplasm treatment.

Naveen Pemmaraju, MD, reviews the currently approved systemic treatment options for myelofibrosis and explains how he decides between treatment regimens.

An expert gives an overview of myelofibrosis and its different types and describes the common challenges of diagnosing patients.

Eytan Stein, MD and Hetty Carraway, MD, wrap up their discussion with a review of the unmet needs in AML treatment and exciting therapies in the pipeline.

Dr Naveen Pemmaraju discusses the current treatment standards for both polycythemia vera and essential thrombocythemia, highlighting the needs of high-risk patients.

Hetty Carraway, MD, explains the importance of bone marrow biopsies in patients with AML receiving treatment with venetoclax + azacitidine.

Naveen Pemmaraju, MD, provides an overview of the three classes of myeloproliferative neoplasms and the signaling pathways that drive therapeutic investigation in the field.

Hetty Carraway, MD and Eytan Stein, MD, discuss the appropriate strategies for the management of cytopenias in patients with AML on venetoclax + azacitidine treatment.

Siddhartha Mukherjee, MD, discusses potential means of targeting chimeric antigen receptor T-cell therapy for patients with acute myeloid leukemia.

Chenyu Lin, MD, discusses the results of a 10-year follow up of patients who underwent allogenic stem cell therapy with the novel cell therapy omidubicel.

Erika P. Hamilton, MD, discusses how researchers are addressing unmet needs for patients with HER2-positive breast cancer.

Raajit Rampal, MD, PhD, discusses the current treatment landscape for patients with myelofibrosis.

Nicolas Gazeau discusses a retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who have received chimeric antigen receptor T-cell therapy.

In an interview with Targeted OncologyTM Nina Shah, MD, discusses the findings from several trials that show the efficacy of daratumumab for patients with multiple myeloma.

Closing out the program, Dr Gilles Salles highlights currently unmet needs in DLBCL and investigational treatments he finds exciting.

Dr Gilles Salles shares his opinion on the presented case’s treatment decision and the regimen he would have selected for the patient.

Gilles Salles, MD, PhD, explains data on the adverse events seen with the pola-BR regimen in R/R DLBCL during the GO29365 clinical trial.

A review of population, dosing, and efficacy data from the GO29365 clinical trial investigating the combination of polatuzumab, bendamustine, and rituximab (pola-BR) for R/R DLBCL.

Dr Salles provides an overview of the available third-line treatment options for patients with R/R DLBCL who are ineligible for or do not wish to receive autologous stem cell transplant or CAR T-cell therapy.

An oncologist describes the typical major challenges of managing patients with R/R DLBCL and the incidence of relapsed or refractory disease.

Gilles Salles, MD, PhD, presents the case of a 51-year-old woman with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Sam S. Chang, MD, MBA, discusses the methods and design of the QUILT 3032 study.

Jennifer Moss, PhD, discusses challenges that impact community cancer care in rural communities.